ACC 2023 | TRILUMINATE Pivotal: Edge-to-Edge Treatment in Patients with Tricuspid Regurgitation

Tricuspid regurgitation is a common and impairing disease. Optimal medical therapy (OMT) is limited, valve surgery is complex, and mortality is not low.

ACC 2023: tratamiento borde a borde en pacientes con insuficiencia tricuspídea

Dr. Paul Sorajja presented the results of the Pivotal Triluminate study to demonstrate the safety and efficacy of edge-to-edge treatment (transcatheter edge-to-edge repair, TEER) in tricuspid regurgitation.

Three hundred and fifty patients with symptomatic tricuspid regurgitation and intermediate or high risk were randomized to receive optimal medical therapy vs. TEER with the Triclip System (half of them received the latest generation TriClip G4).

The primary endpoint (PEP) was a composite of all-cause mortality, tricuspid valve surgery, hospitalization for heart failure, and an improvement in quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ), defined as a 15-point increase at the 12-month follow-up.

Mean age was 78 years and over half the patients were female.

The procedure was safe at 30 days; 98.3% of patients did not experience major complications. There was only one cardiovascular death and two patients presented new-onset renal impairment.

Read also: ACC 2023 | RENOVATE-COMPLEX-PCI: Intravascular Imaging-Guided vs. Angiography-Guided Complex PCI.

The PEP was in favor of TEER (win ratio 1.48; 95% confidence interval: 1.06-2.13). There was no difference in mortality, hospitalization for heart failure, or tricuspid valve surgery.

Quality of life was superior for those who received TEER, with a 12.3-point vs. a 0.6-point increase in those who received OMT (p < 0.001). Likewise, half increased their quality of life by 15 points vs. 26% in the other group.

The proportion of patients with mild or moderate tricuspid regurgitation at 30 days and 12 months was higher in the TEER group compared with the OMT group (87% vs. 4.8%; p < 0.001 and 88.9% vs. 5.6%; p < 0.001, respectively).

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...